

CORRECTION

Open Access



Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Davide Bedognetti^{1†}, Michele Ceccarelli², Lorenzo Galluzzi^{3,4,5}, Rongze Lu^{2†}, Karolina Palucka⁶, Josue Samayoa^{2†}, Stefani Spranger^{7†}, Sarah Warren^{8†}, Kwok-Kin Wong⁹, Elad Ziv¹⁰, Diego Chowell¹¹, Lisa M. Coussens¹², Daniel D. De Carvalho¹³, David G. DeNardo¹⁴, Jérôme Galon¹⁵, Howard L. Kaufman¹⁶, Tomas Kirchhoff¹⁷, Michael T. Lotze¹⁸, Jason J. Luke¹⁹, Andy J. Minn²⁰, Katerina Politi²¹, Leonard D. Shultz²², Richard Simon²³, Vésteinn Thórhósson²⁴, Joanne B. Weidhaas²⁵, Maria Libera Ascierto²⁶, Paolo Antonio Ascierto²⁷, James M. Barnes², Valentin Barsan²⁸, Praveen K. Bommareddy²⁹, Adrian Bot³⁰, Sarah E. Church⁸, Gennaro Ciliberto³¹, Andrea De Maria³², Dobrin Draganov³³, Winson S. Ho³⁴, Heather M. McGee³⁵, Anne Monette³⁶, Joseph F. Murphy³⁷, Paola Nisticò³¹, Wungki Park¹¹, Maulik Patel², Michael Quigley³⁸, Laszlo Radvanyi³⁹, Harry Raftopoulos⁴⁰, Nils-Petter Rudqvist³, Alexandra Snyder⁴¹, Randy F. Sweis¹⁹, Sara Valpione⁴², Roberta Zappasodi^{47,48}, Lisa H. Butterfield⁴³, Mary L. Disis⁴⁴, Bernard A. Fox⁴⁵, Alessandra Cesano⁸, Francesco M. Marincola^{46*} and Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups

Correction to: J Immuno Ther Cancer

<https://doi.org/10.1186/s40425-019-0602-4>

Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

The correction has been implemented in the original article as well.

The publisher apologized for any inconvenience this might have caused.

Author details

¹Sidra Medicine, Doha, Qatar. ²AbbVie, Redwood City, CA, USA. ³Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. ⁴Sandra and Edward Meyer Cancer Center, New York, NY, USA. ⁵Université Paris Descartes/Paris V, Paris, France. ⁶The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. ⁷Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA. ⁸NanoString Technologies, Inc, Seattle, WA, USA. ⁹Perlmutter Cancer Center, New York Langone Health, New York, NY, USA. ¹⁰University of California, San Francisco, CA, USA. ¹¹Memorial Sloan Kettering Cancer Center, New York, NY, USA. ¹²Oregon Health & Science University, Portland, OR, USA. ¹³Department of Medical Biophysics, Princess Margaret Cancer Centre University Health Network, University of Toronto,

Toronto, Canada. ¹⁴Washington University School of Medicine in St. Louis, St. Louis, MO, USA. ¹⁵INSERM, Laboratory of Integrative Cancer Immunology, Equipe Labellisée Ligue Contre le Cancer, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, F-75006 Paris, France. ¹⁶Massachusetts General Hospital, Boston, MA, USA and Replimune, Inc, Woburn, MA, USA. ¹⁷Perlmutter Comprehensive Cancer Center, New York University School of Medicine, New York University Langone Health New York, New York, NY, USA. ¹⁸UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. ¹⁹University of Chicago, Chicago, IL, USA. ²⁰Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA. ²¹Yale School of Medicine, New Haven, CT, USA. ²²The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA. ²³R. Simon Consulting, Potomac, MD, USA. ²⁴Institute for Systems Biology, Seattle, WA, USA. ²⁵University of California, Los Angeles, Los Angeles, CA, USA. ²⁶MedImmune, Gaithersburg, MD, USA. ²⁷Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy. ²⁸Stanford University, Stanford, CA, USA. ²⁹Rutgers University, New Brunswick, NJ, USA. ³⁰Kite, a Gilead Company, Santa Monica, CA, USA. ³¹IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy. ³²Università degli Studi di Genova and Ospedale Policlinico San Martino IRCCS, Genoa, Italy. ³³Calidi Biotherapeutics, San Diego, CA, USA. ³⁴Department of Neurosurgery, Division of Pediatric Neurosurgery, Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA. ³⁵Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ³⁶Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. ³⁷Caprion Biosciences Inc, Montreal, QC, Canada. ³⁸Bristol-Myers Squibb Company, Redwood City, CA, USA. ³⁹Ontario Institute for Cancer Research, Toronto, Ontario, Canada. ⁴⁰Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, USA. ⁴¹Merck & Co, Kenilworth, NJ, USA. ⁴²CRUK Manchester Institute and The Christie NHS Foundation Trust, The University of Manchester, Manchester, UK.

* Correspondence: franco.marincola@refugebiotech.com

[†]Davide Bedognetti, Rongze Lu, Josue Samayoa, Stefani Spranger and Sarah Warren contributed equally to this work.

⁴⁶Refuge Biotechnologies Inc, 1505 Adams Drive, Suite D, Menlo Park, CA 94025, USA

Full list of author information is available at the end of the article



⁴³Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.

⁴⁴University of Washington, Seattle, WA, USA. ⁴⁵Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA. ⁴⁶Refuge Biotechnologies Inc, 1505 Adams Drive, Suite D, Menlo Park, CA 94025, USA. ⁴⁷Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁴⁸Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Received: 14 June 2019 Accepted: 14 June 2019

Published online: 04 July 2019

Reference

1. Bedognetti, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. *J Immuno Ther Cancer*. 2020;7:131. <https://doi.org/10.1186/s40425-019-0602-4>.